EBAMED
EBAMed SA, developer of medical technologies to transform the treatment of cardiac arrhythmias, has appointed experienced specialist Marina Izzo as Chief Executive Officer (CEO). Mrs. Izzo will set the vision for EBAMed’s technology and lead the effort for the next financing round, planned for 2022. Former CEO and co-founder, Adriano Garonna has transitioned to Chief Technology Officer (CTO) and maintains a role on the company’s Board of Directors.
“Marina has strong experience in leading medical device businesses and developing the market for groundbreaking cardiovascular technologies in Europe, North America and China,” said Mr. Giovanni Leo, Chairman of the Board. “Her experience will be invaluable as we realize our mission to shift the paradigm in electrophysiology (EP) from catheter-based ablation therapies to non-invasive EP procedures.”
Mrs. Izzo served as CEO for Cardionovum, an innovative developer of drug coated balloon technology. Prior to that, she was Senior Director of Sales and Marketing at Symetis SA (now part of Boston Scientific), where she established the company as a key competitor in the transcatheter aortic valve implantation (TAVI) market. She has held several leadership roles with Medtronic in Europe and with St. Jude Medical, including Marketing Director for the EMEA Atrial Fibrillation (AF) business. Mrs. Izzo is a graduate of Bocconi University of Milan.
“Many patients fail or cannot undergo conventional invasive therapies such as ablation,” said Mrs. Izzo. “I am very excited to continue exploring the potential of radiation oncology therapies in cardiac medicine and to realize EBAMed’s mission to change the lives of patients living with cardiac arrhythmias”.
Some 53 million people globally1 experience some type of cardiac arrhythmia. For older persons with a history of heart disease, arrhythmia can lead to serious medical complications. The development of a radiation therapy approach, combined with an unique motion monitoring and gating solution to improve target definition and tracking accuracy, could be of substantial value in providing alternative therapy to either drug therapy or catheter-based ablation, and to reduce radiation to innocent myocardium.
About EBAMed
EBAMed is an early-stage, private medical device company. EBAMed is developing a cardiac ultrasound product to improve radioablation for Ventricular Tachycardia, a growing clinical need in the face of the prevalence of heart disease, and aging populations. For more information, visit https://eba-med.com
1 JPMorgan 39th Annual Healthcare Conference, January 2021 - Virtual
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005060/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vodafone Spain and Twilio Partner to Offer Secure and Interactive RCS Messaging to Businesses in Spain23.10.2025 10:00:00 CEST | Press release
81% of consumers prefer RCS over SMS, and 71% of businesses plan to adopt it in the next year. Twilio, the customer engagement platform that powers personalised, real-time experiences for today's leading brands, has announced an extended partnership with Vodafone Spain, one of the country's leading telecommunications operators. This will enable Spanish businesses to access Rich Communication Services (RCS) messaging, revolutionising the way they interact with their customers through rich, interactive and secure communications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023623745/en/ Vodafone Spain has relied on Twilio's global expertise to accelerate the adoption of this next-generation messaging solution, positioning it as the new standard for business communication in the Spanish market. A much needed evolution for mobile communication In a world where personalisation and trust are essential for brand to consumer re
AGC Biologics Partners with Rarity PBC to Advance Life-Saving Gene Therapy for "Bubble Baby Disease"23.10.2025 09:00:00 CEST | Press release
Collaboration will leverage AGC Biologics’ commercial manufacturing experience and proven platforms to seek regulatory approval for a therapy treating the rare immunodeficiency disorder, ADA-SCID. AGC Biologics, your friendly CDMO expert, today announced an agreement with Rarity PBC to provide comprehensive development and Good Manufacturing Practice (GMP) manufacturing for Rarity's gene therapy, RDP-101, for Adenosine Deaminase Severe Combined Immunodeficiency Disorder. If approved by the U.S. Food and Drug Administration, RDP-101 would be the first gene therapy available for commercial use to reverse ADA-SCID in patients within the United States. ADA-SCID is a rare, life-threatening inherited condition that severely compromises the immune system, leaving infants vulnerable to frequent and severe infections. For every million babies born worldwide, it is estimated that between one and five will have this condition. The ADA-SCID disorder caused by an Adenosine Deaminase deficiency is f
KILL TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation23.10.2025 08:01:00 CEST | Press release
TOURISE requests that their press release NewsItemID: 20251022347041 “TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation” be killed. The release was issued in error by TOURISE. A replacement release will be issued on October 23.
TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation23.10.2025 08:01:00 CEST | Press release
Imagine a traveler’s perfect day planning itself, rerouting around a rainstorm, prompting a café to add staff before the lunch rush, suggesting a quiet gallery when crowds swell. This is the promise of Agentic Tourism, an AI-powered operating model introduced in a new white paper by TOURISE and Globant, a digitally native company that helps organizations thrive in a digital and AI-powered future, with strategic contribution from Kearney. The report, titled Tourism’s AI Takeover: Reinventing Travel through Agentic Tourism, presents a practical framework for transforming the tourism experience making it more seamless, intelligent, and emotionally resonant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022347041/en/ TOURISE and Globant Unveil New White Paper on Agentic AI in Tourism In 2024, tourism generated 10.9 trillion dollars, nearly 10 percent of global GDP, and is projected to reach 16.5 trillion dollars by 2035. AI
Bureau Veritas:Robust and Consistent Revenue Performance Delivered in Q3 2025; FY 2025 Outlook Reaffirmed23.10.2025 07:30:00 CEST | Press release
Bureau Veritas (BOURSE:BVI): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022995674/en/ Hinda Gharbi, CEO Bureau Veritas Q3 2025 Key figures1 › Revenue of EUR 1,583.7 million, up 2.3% year-on-year and up 6.3% organically › A very strong organic growth from Marine & Offshore at 16.2%; solid recovery of Buildings & Infrastructure at 7.1% organically; strong organic growth maintained for both Industry and Certification, at 6.9% and 5.9% respectively, against challenging comparables; moderate organic growth for Consumer Products Services at 3.5% and Agri-Food & Commodities at 2.5% › Positive scope effect of 0.8%, from the accelerated pace of bolt-on acquisitions (+3.1% contribution) realized, net of disposals (-2.3% contribution) › Negative currency impact of 4.8%, resulting from the euro’s appreciation against most currencies Q3 2025 Highlights › Continued progress in implementing the LEAP I 28 strategy, delivering results
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom